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Abstract
Study Design: Scoping review.
Objective: To describe activity, themes and trends in degenerative cervical myelopathy (DCM) research over the past 20 years
with a view to considering DCM research inefficiency.
Methods: A systematic review of MEDLINE and Embase for “Cervical” AND ”Myelopathy” was conducted following PRISMA
guidelines. Full-text papers in English, exclusively studying DCM, published between January 1, 1995 and December 31, 2015 were
considered eligible. Country of origin, number of papers published, number of patients studied, research theme, and year of
publication were assessed. Comparison was made between developed and developing countries.
Results: A total of 1485 papers and 4117051 patients were included. Japan published more papers (450) than any other country
while the United States studied the greatest number of patients (3 674737). Over 99.4% of papers and 78.6% of patients were
from developed countries. The number of papers (r ¼ 0.96, P < .001) and patients (r ¼ 0.83 P < .001) studied each year increased
significantly overall and for both developed (r ¼ 0.93, P < .001; r ¼ 0.81, P < .001) and developing countries (r ¼ 0.90, P < .001;
r¼ 0.87, P < .001). Surgery was the most prevalent theme (58.3% papers; 55.7% patients) for developed and developing countries.
Research from developing countries showed greater thematic variability.
Conclusions: DCM research activity is increasing internationally, with surgery remaining the focus. Research output has pre-
dominantly been from developed countries; however, the rate of growth for developed and developing countries is comparable.
Keywords
cervical cord, cervical vertebrae, spondylosis, spinal osteophytosis, spinal cord diseases, chronic disease
Introduction
Degenerative cervical myelopathy (DCM) is a disabling syn-
drome of symptomatic spinal cord compression secondary to
degenerative changes in the cervical spine.1,2 DCM is com-
mon,2-4 with an estimated prevalence of up to 5% in the pop-
ulation older than 40 years,1 which is expected to increase as
global populations age.2 DCM patients experience a wide range
of disabling symptoms.1 Limb pain, weakness, stiffness, and
numbness are prevalent. Neck stiffness and neck pain are com-
monly reported, as are loss of dexterity, bladder and bowel
dysfunction, and gait problems.5 Ultimately the disease is pro-
gressive6 and can, in very severe cases, result in paralysis.7
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Surgical decompression, independent of surgical approach,
is currently the only evidence-based treatment that has been
shown to halt disease progression, but existing neurological
damage is often permanent.8,9 Even with current gold standard
surgical care, most patients retain lifelong disabilities.9 A
recent study demonstrated that DCM severely affects quality
of life; Short Form–36 health survey (SF-36) scores in DCM
patients were lower than most chronic diseases including, can-
cer, hypertension, chronic lung disease, diabetes, and
depression.10
One implication is a large and growing economic burden
from the lifelong loss of productivity and the lifelong health
and social care that DCM patients often require.7 A large and
increasing clinical need exists to optimize care and reduce
suffering, which must promptly be addressed by health care
research.
Substantial international investment is made in research by
governments and charities, but often with poor efficiency and
failure to meet patient needs. This results in research waste11
with both economic and human consequences,11 serving to
decelerate the speed of progress through mechanisms includ-
ing failure to consolidate currently available evidence. Whilst
some inefficiency is unavoidable, much cannot be justified. In
their seminal paper, Chalmers et al12 identified a number of
factors contributing to research wastage, including research
duplication and failure to establish research priorities.
Reviewing what is already known and setting research prio-
rities before conducting further primary research is key to
reducing inefficacy.12
The objective of this review is to provide a systematic over-
view of global DCM research from the past 20 years, identify-
ing the research type, location, themes and trends including
areas of potential inefficiency and comparison between devel-
oped and developing countries.
Methods
A systematic review was conducted in accordance with the
PRISMA guidelines.13A search of Embase and MEDLINE for
[“Cervical”] AND [”Myelopathy”] for papers published from
January 1, 1995 to December 31, 2015 was performed for all
studies considering cervical myelopathy secondary to chronic
compression of the spinal cord.14,15 Animal studies, case
reports, letters, editorials, reviews, technical notes, commen-
taries, proposals and corrections were excluded.
Titles and abstracts were screened for relevance, and subse-
quently full-text papers were screened for eligibility according
to the following criteria:
 Primary clinical trial
 DCM is the primary condition being addressed in the
paper
 English, full text
Papers were screened by 3 authors [SG, CO, ODM] and data
was extracted independently by 2 authors [SG, CPO] using a
piloted proforma. Discrepancies were settled by discussion and
mutual agreement.
Following screening the following information was
recorded for each paper:
 Country of corresponding author
 Year of publication
 Research theme
 Number of patients
 Whether a surgical or a nonsurgical cohort was studied
 Whether investigating the surgery itself was the primary
objective of the research study
Research themes were initially developed using included
studies from our previous systematic reviews.14,15 These themes
were then piloted and iteratively refined in a random subset of
200 papers shortlisted for this review until a mutually exclusive
and usable taxonomy (as mutually agreed by all authors) had
been developed. A hierarchy was used such that each paper was
categorized into the single theme which the authors felt best
described the overall focus of the paper. The following 8 themes
were used for categorization:
1. Functional outcome measures and their validation, such
as the Japanese Orthopaedic Association Myelopathy
Evaluation Questionnaire (JOAMEQ)
2. Imaging and its role in diagnosis or follow-up
3. Molecular and genetic investigations
4. Prognostication based on patient demographics and
baseline characteristics
5. Electrophysiological investigations
6. Surgical technique, approach or strategy as the focus of
the paper
7. Epidemiological studies
8. Other papers not covered by the above themes
The CIA World Factbook definitions were used to divide
countries into developed or developing categories.16
Statistical analysis was used to detect trends in research
themes across time. Correlations were performed using Spear-
man’s rank correlation coefficient, using SPSS Version 25 (IBM
Corporation, Armonk, NY). Significance was set at P < .05. We
report mean+ standard deviation unless otherwise specified.
Results
The search strategy returned 3944 papers, of which 962 were
excluded. Following title, abstract, and full-text screening, a
total of 1485 full-text papers were included, assessing
4 117 051 patients (Figure 1). A total of 79% (1174) of papers
studied a surgical cohort, with 45% (675) of total papers having
surgical technique as the dependent variable.
Between 1995 and 2015, DCM research was conducted in
53 countries (Figure 2). Japan was the country with the highest
output of DCM research in terms of number of papers pub-
lished, with 30.3% of total DCM papers over the 20-year period
(Table 1); United States (19.5%) and China (12.0%) were the
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second and third most research-active countries in terms of
papers published. However, United States studied the greatest
number (89.2%) of DCM patients. Japan (5.6%) and Taiwan
(3.6%) were the second and third most research-active in terms
of number of DCM patients studied (Table 2).
The number of countries participating in DCM research
became more diverse over the study period. In 1995, 19 DCM
studies were published from 6 countries, while in 2015, 189
DCM studies were published from 30 countries (Figure 3), a
statistically significant increase, r ¼ 0.96, P < .001.
The number of patients studied per year increased over the
study period from 1577 patients in 1995 to 330 935 in 2015, a
statistically significant increase, r ¼ 0.83 P < .001. However,
this overall trend was accentuated by several US national
database studies with very high patient numbers between
2006 and 2015.17-19
While the absolute number of papers from Japan increased
from 10 in 1995 to 31 in 2015, the percentage of DCM papers
from Japan fell from 52.6% in 1995 to 16.4% in 2015 (Figure
3A). The percentage of papers from the United States was
relatively constant between 1995 (21.1%) and 2015 (21.7%).
The absolute number of papers from China increased from 1 in
1995 to 41 in 2015, an increase in percentage of total papers
from 5.3% in 1995 to 22.2% in 2015.
In the first decade, Japan was dominant in publishing data
on the greatest number of patients (Figure 3B). In the second
decade, papers with very high patient numbers from the United
States led to the United States becoming the country studying
the greatest number of patients per year and the greatest num-
ber in total over the whole study period.
A total of 28 developed and 25 developing countries pub-
lished DCM research between 1995 and 2015, using CIA
World Factbook definitions.16 Developed countries published
1167 (78.6%) studies on a total 4 092 626 (99.4%) patients
compared with 318 (21.4%) studies on a total of 24 425
(0.6%) patients from developing countries.
Between 1995 and 2015, developed countries showed a sig-
nificant increase both in number of papers published, r ¼ 0.93
P < .001 and in number of patients studied, r ¼ 0.81, P < .001.
In the same time period, developing countries showed compa-
rable significant increases both in number of papers published,
r ¼ 0.90, P < .001 and in number of patients studied, r ¼ 0.87,
P < .001 (Figure 4). In context, over the same 1995-2015
period, the total number of papers published per year indexed
in PubMed increased significantly with a coefficient of r ¼
0.99, P < .001.
In terms of number of papers, surgery was by far the most
prevalent theme with a total of 866 papers, making up 58.3% of
total DCM papers (Table 3), followed by imaging, which was
the subject of 17.5% of total papers.
Surgery was the research theme for which the greatest num-
ber of patients were studied, commanding a total of 2 294 089
(55.7%) patients (Table 3). While few in number (n ¼ 20), the
large patient numbers in epidemiological studies led to this
theme being second most prevalent in terms of patient numbers
with a total of 1 469 402 (35.7%) patients.
In terms of number of papers, surgery was the most preva-
lent theme in every year of study between 1995 and 2015
(Figure 5A), consistently representing 40% to 75% of papers
each year. Imaging was consistently the second most prevalent
research theme with 10% to 20% of papers published on this
theme each year.
Between 1995 and 2015, there was a small but significant
increase in the percentages of prognostication papers, r¼ 0.45,
P¼ .042 and functional outcome papers, r¼ 0.53, P¼ .015. In
addition, there was a small but significant decrease in the per-
centage of electrophysiology papers, r ¼ 0.58, P ¼ .006.
Surgery remained the most prevalent DCM research theme
when data was analyzed in terms of patient numbers (Figure
5B). However, there was more variability in the percentage of
patients in surgically themed papers between years compared
with the percentage of papers (Figure 5A and B). Epidemiol-
ogy was the second most prevalent DCM research theme in
terms of patient numbers, although the majority of these
patients were represented in a small number of large studies,
particularly in 2013.
Over the study period 1995-2015, there was a significant
decrease in the percentage of patients in imaging studies, r ¼
0.76, P < .001, and electrophysiology studies, r¼0.59, P¼
.005. There was a significant increase in number of patients
included in molecular studies, r ¼ 0.62, P ¼ .003.
The percentage of papers of each research theme were sim-
ilar for developed and developing countries (Figure 6A). The
highest percentage of papers were published on a surgical
theme for both developed (56.8%) and developing (63.8%)
countries. The second highest percentage of papers were pub-
lished on imaging for developed countries (18.2%) and devel-
oping countries (15.1%).
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) flow diagram of search strategy.
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Surgical themed papers included the largest percentage of
DCM patients in both developed (55.7%) and developing coun-
tries (62.7%). However, the percentage distributions for
Figure 2.World heatmaps showing degenerative cervical myelopathy (DCM) research output by country between 1995 and 2015 in terms of
(A) number of papers and (B) number of patients. The higher the output the darker the shade of blue in which the country is represented. Japan
and the United States were the greatest producers of DCM research.
Table 1. Top 10 Countries by Degenerative Cervical Myelopathy
Research Paper Output Between 1995 and 2015.a
Country Papers, n (%) r P
Japan 450 (30.3) 0.82 .001
United States 290 (19.5) 0.86 .001
China 178 (12.0) 0.88 .001
South Korea 71 (4.8) 0.87 .001
Canada 57 (3.8) 0.83 .001
India 57 (3.8) 0.77 .001
Germany 49 (3.3) 0.48 .027
United Kingdom 41 (2.7) 0.53 .013
Italy 34 (2.3) 0.33 .146
Czech Republic 28 (1.9) 0.47 .031
Other 230 (15.6) 0.92 .001
a Spearman’s correlation coefficients were calculated to identify trends in
growth of paper output by country (r) for which significance testing was con-
ducted and P values are reported.
Table 2. Top 5 Countries by Number of Degenerative Cervical
Myelopathy Research Patients Between 1995 and 2015.a
Country Patients n (%) r P
United States 3 674737 (89.2) 0.74 .001
Japan 230176 (5.6) 0.92 .001
Taiwan 148206 (3.6) 0.85 .001
China 16597 (0.4) 0.80 .001
Canada 14670 (0.4) 0.82 .001
Other 32665 (0.8) 0.83 .001
a Spearman’s correlation coefficients (r) were calculated to identify trends in
the number of patients on which data was published each year by each country.
Significance testing was conducted and P values are reported.
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number of patients in each theme were not similar for devel-
oped and developing countries (Figure 6B).
In developed countries, 35.9% of DCM patients were
included in epidemiological papers, compared to 1.6% of
patients in developing countries. In contrast, 14.1% of patients
were included in imaging papers in developing countries, com-
pared with 0.4% in developed countries. Whilst the surgical
theme was world-wide predominant, there was more diversity
in study themes for developing countries with higher percen-
tages of patients included in papers studying prognostication,
functional outcomes, electrophysiology, and molecular themes.
In contrast, the majority of nonsurgical DCM patients in devel-
oped countries were included in epidemiological papers.
Discussion
DCM research is international and increasing year-on-year,
both in terms of number of papers published and number of
patients studied. This includes both developed and developing
countries, where growth is comparable. The majority of
research is evaluating patients undergoing surgery, and in par-
ticular the surgery itself. Although significantly lower in num-
ber, growing areas of research interest include prognostication,
development of functional outcomes, and molecular studies.
Is Surgery Being Overresearched?
DCM treatment is predominantly managed by surgeons, with
decompressive surgery the only evidence-based treatment.8,9 It
has been shown to halt disease progression and offer mean-
ingful, albeit generally incomplete, recovery. Consequently, a
focus on surgical research might be expected and we identified
that 79% of papers studied patients undergoing surgery, with
45% of papers evaluating the benefit of a surgical technique.
This is in keeping with recent review of the top 100 most-cited
spinal surgery papers,20 which included 3 studies of DCM, all
of which concerned surgical technique.
Figure 3. (A) Top 10 countries in terms of number of degenerative cervical myelopathy (DCM) research papers published. Japan was dominant
in the first decade, publishing 32% to 56% of total papers each year. In the second decade, Japan’s output was frequently 30% or less of total
international output. (B) Top 5 countries by number of patients studied. Japan and the United States were consistently the top 2 countries in
terms of number of DCM patients studied each year. The relative dominance of the United States in 2007-2009 was due to a peak in number of
patients studied in US studies.
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This particular focus is likely to represent an example of
research inefficiency for a number of reasons. First, not all
patients undergo surgery. It is currently estimated that most
DCM patients never gain a diagnosis1,21,22 and not all patients
are managed with surgery.22-24 Second, fundamentally impor-
tant aspects of DCM, such as the natural history of disease and
its exact etiology remain unknown.25 Third, the synthesized
evidence of surgical research has not found additional benefit
for one surgical approach over another.23 Fourth, despite a
recognized need, little research has aimed at finding strategies
to improve recovery.26,27 Finally, the majority of DCM
research consists of low evidence design.14
In an attempt to provide high-level evidence on the signifi-
cance of surgical technique, the ongoing Cervical Spondylotic
Myelopathy Surgical (CSM-S) Trial (NCT02076113) is due to
report and may offer some closure here.28 Nevertheless, there
are important surgical questions that remain to be answered.
For example, we have previously demonstrated that most stud-
ies have focused on patients undergoing surgery for the first
time and the role of repeat surgery remains relatively unex-
plored.14 Additionally the evidence base defining the timing,
especially for acute central cord syndrome without instability,
remains weak.23
In summary, while ongoing surgical research is required,
its present direction likely contains inefficiencies. Global
energy and enthusiasm could be better harnessed to address
knowledge gaps.
The Past and the Future
We found significant increases in absolute output in all 8 DCM
research themes. While surgery remained predominant, there
was relative growth for prognostication, functional outcome
and molecular research studies. Conversely, there has been a
relative decrease in electrophysiology studies.
These emerging themes, from our perspective, align with
important and unaddressed issues. The natural evolution of
DCM is unknown and currently unpredictable25; in some
Figure 4.Number of papers published increased significantly overall and for both developed and developing countries between 1995 and 2015.
Table 3. Degenerative Cervical Myelopathy Research by Theme.a
Theme Number of papers (%) r P Number of patients (%) r P
Surgery 866 (58.3) 0.05 .819 2294089 (55.7) 0.12 .610
Imaging 260 (17.5) 0.02 .947 18564 (0.4) 0.76 .001
Prognostication 115 (7.8) 0.45 .042 170741 (4.1) 0.20 .372
Electrophysiology 91 (6.1) 0.58 .006 6712 (0.2) 0.59 .005
Functional Outcome 61 (4.1) 0.53 .015 8777 (0.2) 0.07 .749
Other 45 (3.0) 0.36 .109 146309 (3.6) 0.27 .242
Molecular 27 (1.8) 0.33 .139 2457 (0.1) 0.62 .003
Epidemiology 20 (1.4) 0.33 .149 1469402 (35.7) 0.42 .061
aSurgery and imaging were the most prevalent themes, together accounting for over 75% of papers published between 1995 and 2015. Spearman’s correlation
coefficients (r) were calculated to assess trends in percentages of papers and patients for each theme between 1995 and 2015, for which significance testing was
conducted and P values are reported. Significant findings are in boldface.
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individuals, symptoms remain mild over extended periods of
time while in others, disease progression is accelerated.23,29
This uncertainty creates a number of clinical challenges, none
more so than the timing of surgery23 and detection of myelo-
pathy from asymptomatic spinal cord compression.30
Most existing DCM assessments rely on qualitative grading14
with few examples of quantitative assessments, and these are
therefore poorly placed to answer current research questions.31
Moreover, current diagnostic tools have been unable to represent
spinal cord damage. This has undoubtedly led the move toward
new assessment techniques, including diffusion tensor imaging32
and gait analysis.33 Beyond tracking differing disease profiles,
there is increasing interest in the biological basis of DCM, such
as genetics.34 A better understanding of the disease process will
contribute to new treatment development.
The reasons for declining interest in electrophysiology is
unclear; as a quantitative assessment tool it could be an
improvement on current outcomes assessments.14,31 More-
over, it has been shown to be of value in detecting subclinical
myelopathy.35 The potential is likely undermined with
declining access and patient interest; in the United Kingdom,
almost every hospital has a magnetic resonance imaging scan-
ner but very few have neurophysiology services and in our
experience, patients tolerate but would prefer not to undergo
the procedure.
As depicted in Figure 6B, the percentage of patients in epi-
demiological papers is much smaller for developing countries
compared with developed countries. This likely reflects the
lack of national data banks in many developing countries,
which is a key area of development for the future.
Research From Developing Countries
The Global Forum for Health Research estimated that total
public funding for health research in developing countries was
US$2.5 billion per year, representing just 3% of total global
funding for health research.36 In contrast, at the turn of the
millennium, low and middle-income countries were estimated
to represent 85% of the world’s population, 92% of global
disease burden but just 10% of global funding for health
Figure 5. Trends in degenerative cervical myelopathy (DCM) research themes between 1995 and 2015. (A) In terms of number of papers,
surgery was the most prevalent DCM research theme every year between 1995 and 2015. (B) In terms of number of patients, surgery remained
the most prevalent research theme, while epidemiology was the second most prevalent theme.
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research.37 Despite this, the United Nations Educational, Sci-
entific and Cultural Organisation estimates that 27% of
researchers work in developing countries.38
Indeed, DCM is a global problem,9 which is increasingly
common with global aging populations39 and our finding of
active and growing research participation in developing coun-
tries is reassuring, and aligns with the World Health Organiza-
tion objective that “all nations should be producers and users of
research.”40
The involvement of developing countries can also offer
novel insights. An important example of this within neurosur-
gery is the BEST TRIP trial,41 which conducted a randomized
trial of intracranial pressure monitoring for traumatic brain
injury. For DCM, where the prevalence of DCM subtypes dif-
fers with ethnicity,2 this may be essential.
Increasing Research Efficiency
Health research inefficiency is ubiquitous.11 However, other
fields have acknowledged and taken steps to counteract this
through research priority setting partnerships, which are tak-
ing place internationally42 and recognized to improve
efficiency.12 The James Lind Alliance in the United King-
dom, Global Evidence Mapping in Australia, and the Deep
Inclusion Method/Choosing All Together in the United
States, are examples of multistakeholder partnerships involv-
ing patients and the public that have enjoyed success.42 Such
partnerships have already shown promise in diabetes,43 head
and neck cancer,44 psoriasis,45 and kidney cancer46 among
many other diseases.
In DCM, in the context of our findings and the many sig-
nificant unmet needs, such a process is an important next step
for the field. Partnerships involve patients, families, carers, and
health professionals from multiple disciplines and can elicit
and prioritize research questions. Based on our findings, this
needs to be a global process, in order to support the clear,
ongoing, international efforts to advance care in DCM.
Limitations
This review was designed to provide an overview of DCM
research, and consequently extracted common data elements
only. Inherently, this will have created some limitations in the
interpretation of the data. For example, papers were attributed
to address of the corresponding author, which therefore will not
have accounted for multinational research. Moreover, the
grouping themes were developed by the authors, based on a
more focused systematic14,15 review; retrospective and pro-
spective cohorts were not separated. Additionally, no attempt
was made to distinguish datasets used for multiple purposes; it
is not possible to rule out inclusion of individual patients in
more than one paper and therefore the number of patients stud-
ied is likely to be lower than reported. This said, we feel that the
findings overall reflect the literature, and given the significant
number of studies included, serve as an accurate overview of
the field in the past 20 years.
Conclusion
DCM research is conducted globally and is increasing year on
year. Surgery has been a major focus of research so far, which
has overlooked many important knowledge gaps. A priority-
setting partnership would improve efficiency and allow the
global appetite for research to be better harnessed in delivering
much needed advancement.
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